Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall
A mixed trial could hurt a kidney drug's chances of full approval.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”)...
Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that...